Stoke Therapeutics/$STOK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Stoke Therapeutics

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Ticker

$STOK
Primary listing

Industry

Biotechnology

Employees

128

ISIN

US86150R1077

STOK Metrics

BasicAdvanced
$632M
13.20
$0.88
1.20
-

What the Analysts think about STOK

Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.

Bulls say / Bears say

Stoke Therapeutics' lead candidate, zorevunersen (STK-001), has demonstrated substantial and durable reductions in seizure frequency and improvements in cognition and behavior in Dravet syndrome patients, indicating strong therapeutic potential. (investorplace.com)
The FDA has granted Breakthrough Therapy Designation for zorevunersen, facilitating expedited development and review processes, which could accelerate its path to market. (stocktitan.net)
Analysts have maintained a 'Strong Buy' rating for STOK, with an average 12-month price target of $26.00, suggesting significant upside potential from current levels. (stockanalysis.com)
Recent insider selling, including the CEO's sale of 10,382 shares, may signal a lack of confidence in the company's near-term prospects. (etfdailynews.com)
The departure of CEO Dr. Edward Kaye introduces leadership uncertainty, which could impact strategic direction and investor confidence. (stockanalysis.com)
Despite positive clinical data, the company reported a net loss of $25.7 million in Q2 2024, highlighting ongoing financial challenges that may necessitate additional funding. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

STOK Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

STOK Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $STOK

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs